Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06731335 | Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN | PHASE2 | RECRUITING | 30 | — | — | Mar 5, 2025 | Dec 1, 2026 | Mar 30, 2025 | 2 | Canada |
Recruitment rate and withdrawal rate (Acceptability and feasibility study)
| Arm | Type | Description |
|---|---|---|
| Intervention Arm with Psilocybin | EXPERIMENTAL | Intervention Arm with Psilocybin 25 mg single dose PO + psychological support |
| Placebo | PLACEBO_COMPARATOR | Placebo (Active) Dextromethorphan 400 mg single dose PO + psychological support |
| Name | Type | Description |
|---|---|---|
| Psilocybin | DRUG | PSILOCYBIN (PEX010) 25 mg PO single dose |
| Active Placebo | DRUG | Dextromethorphan 400 mg PO single dose |
Inclusion Criteria: * 18-65 years of age * Diagnosis of chronic neuropathic pain as determined by a pain specialist * Moderate-to-severe neuropathic pain determined by Patient Reported Outcomes Measurement Information System (PROMIS) * Previous trials of at least two medications recommended in the ...